At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
VIA-2291 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
In Brief
A Phase 2 clinical trial evaluating VIA-2291 and Placebo for Coronary Artery Disease. Completed, enrolled 191 participants across 12 sites in 2 countries.
Detailed Summary
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesCanada, United States
CollaboratorsMontreal Heart Institute
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionAug 2008
Study CompletionSep 2008
TodayJul 2026
First PostedAug 1, 2006
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.9 years ago
Interventions
VIA-2291drug
oral dosing, 1 time daily for 12 or 24 weeks
Placebodrug
oral dosing, 1 time daily for 12 or 24 weeks